BioStock: Evaxion receives NIH grant for gonorrhoea vaccine

Things continue to move in the right direction for Evaxion Biotech. During 2022, the company has reached several key milestones, including the expanded DNA oncology vaccine programme into non-small cell lung cancer. Now, Evaxion and its partner in Massachusetts, UMass Chan Medical School, announces, that they have received a grant from the U.S. National Institutes of Health for the development of a gonorrhoea vaccine candidate.

Read the article at biostock.se:

https://www.biostock.se/en/2022/09/evaxion-receives-nih-grant-for-gonorrhoea-vaccine/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/